Internal Medicine
Systematic Review: Corticosteroids as Standalone or Add‐on Treatment for Sore Throat
5 May, 2020 | 03:36h | UTCCorticosteroids as standalone or add‐on treatment for sore throat – Cochrane Library
Summary: Corticosteroids as standalone or add‐on treatment for sore throat – Cochrane Library
New NICE Coronavirus Rapid Guidelines
3 May, 2020 | 22:46h | UTC- COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital – National Institute for Health and Care Excellence
- COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response – National Institute for Health and Care Excellence
- COVID-19 rapid guideline: children and young people who are immunocompromised – National Institute for Health and Care Excellence
See Previous NICE Coronavirus Guidelines: Rapid guidelines and evidence summaries – National Institute for Health and Care Excellence
Consensus Document: Restarting Planned Surgery in the Context of the COVID-19 Pandemic
3 May, 2020 | 22:43h | UTCRelated: New Scoring System to Prioritize Medically Necessary Operations (report and commentary)
New Observational Studies Confirm the Safety of Renin–Angiotensin–Aldosterone System Blockers in Patients with Covid-19
3 May, 2020 | 22:32h | UTCStudy 3: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 – New England Journal of Medicine
Commentary: Blood Pressure Drugs Don’t Increase Coronavirus Risk, Studies Find – The New York Times
See also: Observational Study: Renin-Angiotensin System Inhibitors are Not Associated with Severity or Mortality in Hospitalized Patients with Coronavirus Disease (2 other studies on the subject)
Case Series: Characteristics of Ischemic Stroke Associated with COVID-19
3 May, 2020 | 22:18h | UTCCommentary: Expert reaction to study looking at COVID-19, ischaemic stroke and blood clots – Science media Centre
Related: Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young – New England Journal of Medicine AND Coronavirus’s new mystery: It’s causing strokes in healthy people – Vox AND What’s Behind the Sharp Increase in Large-Vessel Stroke Risk in Young, Healthy COVID-19 Patients? – Neurology Today
Short Review: Coagulopathy Associated with COVID-19
3 May, 2020 | 22:09h | UTCCoagulopathy associated with COVID-19 – Canadian Medical Association Journal
Case Series: QT Intervals in Patients with COVID-19 Treated with Hydroxychloroquine Alone or in Combination with Azithromycin
3 May, 2020 | 22:01h | UTCCommentary: Beth Israel Deaconess Medical Center – Beth Israel Deaconess Medical Center
Related Studies: The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection – Circulation: Arrhythmia and Electrophysiology (link to abstract – $ for full-text) AND [Preprint] QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin – medRxiv
FDA Issues Emergency Use Authorization for the Use of Remdesivir to Treat COVID-19
3 May, 2020 | 22:03h | UTCSee also: Remdesivir: A Non-Antiviral Antiviral Drug? – Forbes
[Abstract Only] Meta-Analysis: Prevalence of Harmful Diagnostic Errors in Hospitalized Adults
3 May, 2020 | 21:45h | UTCPrevalence of harmful diagnostic errors in hospitalised adults: a systematic review and meta-analysis – BMJ Quality & Safety (link to abstract – $ for full-text) (via @brhospitalist)
Related Commentary on Twitter
Systematic review of 22 UK studies found that 14 common diagnoses, including malignancy and pulmonary embolism, accounted for more than half of missed or delayed diagnoses in hospital patients. @BMJ_Qual_Saf https://t.co/1JypG7idlJ pic.twitter.com/YxKeiZr5x0
— AHRQ (@AHRQNews) May 1, 2020
Classification of the Cutaneous Manifestations of COVID‐19 with 375 Illustrative Cases
1 May, 2020 | 03:43h | UTCRelated: Journal articles on coronavirus with relevance for skin diseases and dermatology – Centre of Evidence Based Dermatology, University of Nottingham AND Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak – Journal of the American Academy of Dermatology
Great atlas with the different cutaneous manifestations of Covid-19.
CO-RADS – A Categorical CT Assessment Scheme for Patients with Suspected COVID-19
1 May, 2020 | 03:48h | UTC
Study: Within 19 Days After Symptom Onset, 100% of Patients Test Positive for IGG
1 May, 2020 | 03:33h | UTCAntibody responses to SARS-CoV-2 in patients with COVID-19 – Nature Medicine
Commentary: Expert reaction to antibody response in COVID-19 patients – Science Media Centre
Small Observational Study Suggests Prophylactic LMWH Can Prevent COVID‐19 Disseminated Intravascular Coagulopathy
1 May, 2020 | 03:26h | UTCCOVID‐19 Coagulopathy in Caucasian patients – British Journal of Haematology
Treatment Considerations for COVID-19: A Critical Review of the Evidence
1 May, 2020 | 03:20h | UTC
[Abstract Only] Cohort Study: Effect of Hydroxychloroquine and Azithromycin on the QT Interval in Patients with Covid-19
1 May, 2020 | 03:10h | UTCThe Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection – Circulation: Arrhythmia and Electrophysiology (link to abstract – $ for full-text)
COVID-19 and the Cardiovascular System: Implications for Risk Assessment, Diagnosis, and Treatment Options
1 May, 2020 | 03:18h | UTCRelated Guidelines: COVID-19 rapid guideline: acute myocardial injury – National Institute for Health and Care Excellence AND ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic – European Society of Cardiology AND Management of Acute Myocardial Infarction During the COVID-19 Pandemic – Journal of the American Academy of Cardiology
Perspective: Urging Caution on Remdesivir
1 May, 2020 | 03:07h | UTCUrging Caution On Remdesivir – Forbes
Related: About Remdesivir and About “Game-Changers” – Science Translational Medicine AND Conflicting Remdesivir Trial Results Released; Experts Urge More Research – Health Policy Watch AND Is remdesivir a miracle drug to cure coronavirus? Don’t get your hopes up yet – The Conversation AND PulmCrit- First placebo-controlled RCT on remdesivir for COVID-19 – PulmCrit AND Remdesivir: the antiviral drug is being touted as a possible coronavirus treatment – but will it work? – The Guardian
“While I have enormous respect for the Institutes and their leaders, releasing the preliminary news without sharing the data behind it is highly irresponsible.”
Review: Neurologic Comorbidities and Complications in Patients Hospitalized for COVID-19
1 May, 2020 | 03:03h | UTCRelated Studies: Neurologic Features in Severe SARS-CoV-2 Infection – New England Journal of Medicine AND Neurologic Manifestations Common in Hospitalized Patients with Covid-19 (study and commentaries)
COVID-19: ICU Delirium Management During SARS-CoV-2 Pandemic
1 May, 2020 | 02:54h | UTCCOVID-19: ICU delirium management during SARS-CoV-2 pandemic – Critical Care
ACR Guidance for the Management of Patients with Rheumatic Disease During the COVID‐19 Pandemic
1 May, 2020 | 02:42h | UTC
We Need to Flatten the ‘Other’ Coronavirus Curve, Our Looming Mental Health Crisis
1 May, 2020 | 02:45h | UTCRelated: Health Care Workers Seek to Flatten COVID-19’s ‘Second Curve’—Their Rising Mental Anguish
Clinical Determinants for Fatality of 44,672 Patients with COVID-19
1 May, 2020 | 02:48h | UTCClinical determinants for fatality of 44,672 patients with COVID-19 – Critical Care
Systematic Review: No Evidence to Support the Use of Aspirin for the Prevention of Dementia
1 May, 2020 | 02:38h | UTCRelated Randomized Trial: Aspirin Not Beneficial for Reducing the Risk of Dementia, MCI, or Cognitive Decline
Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
30 Apr, 2020 | 04:31h | UTCCommentaries: First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed – The Lancet AND Expert reaction to trial of remdesivir in adults – Science Media Centre
See also: [Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
Related Commentary on Twitter
With all the hype about Remdesivir today @TheLancet has decided to lift the embargo and release this placebo-controlled multicenter study done in China that showed no benefit https://t.co/ZdmKfnWLyw
— Carlos del Rio (@CarlosdelRio7) April 29, 2020
[Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
30 Apr, 2020 | 04:28h | UTCCommentaries: Hopes rise on coronavirus drug remdesivir – Nature AND The COVID-19 research news rollercoaster is running again: STAT News + Gilead’s remdesivir – HealthNews Review
See also: Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19